Back to top
more

Bioventus (BVS)

(Delayed Data from NSDQ)

$6.18 USD

6.18
526,076

-0.34 (-5.21%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $6.18 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Bioventus Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Bioventus stock based on the movements in the options market lately.

Zacks Equity Research

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 33.33% and 2.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

by Abhinab Dasgupta

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Zacks Equity Research

Ensign Group Invests in Growth With New Facility Acquisitions

by Zacks Equity Research

ENSG continues its strategic growth with new acquisitions across Washington and California.

Zacks Equity Research

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Centene & HMHB Hawaii Expand Partnership for Maternal Care

by Zacks Equity Research

CNC's Ohana Health Plan and HMHB Hawaii expand maternal care, enhancing support for mothers and babies through strategic investment and community partnerships.

Zacks Equity Research

Centene's Meridian Unit Secures a D-SNP Contract in Illinois

by Zacks Equity Research

CNC's Meridian Health Plan wins a D-SNP contract in Illinois, expanding enhanced managed care for Medicare-Medicaid-eligible individuals. The deal is likely to boost Centene's foothold and membership base in the state.

Zacks Equity Research

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 66.67% and 5.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 30.61% and 2.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

by Zacks Equity Research

Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.

Zacks Equity Research

Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Bioventus (BVS) Matches Q3 Earnings Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Bioventus (BVS) This Year?

by Zacks Equity Research

Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Sundeep Ganoria headshot

Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?

by Sundeep Ganoria

Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.

Sundeep Ganoria headshot

Bioventus Surges 73% in Three Months: Time to Buy the Stock?

by Sundeep Ganoria

BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.

Zacks Equity Research

Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

by Zacks Equity Research

Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.

Zacks Equity Research

Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus

by Zacks Equity Research

As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.

Zacks Equity Research

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

by Zacks Equity Research

The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.

Zacks Equity Research

Here's Why Investors Should Consider Buying Corcept Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Talen Energy, CBRE, 3M in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

by Zacks Equity Research

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

Zacks Equity Research

Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market

by Zacks Equity Research

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.